Cancer treatments using combinations of type 2 MEK and ERK inhibitors
The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD 523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 2 MEK inhibitor, or other MEK inhibitors, or pharmaceutically acceptable salts thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
1. A method of treating or ameliorating the effects of a cancer in a subject in need thereof comprising administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 2 MEK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer,
wherein the type 2 MEK inhibitor is selected from the group consisting of GDC-0623, MEK162, trametinib, pharmaceutically acceptable salts thereof, and combinations thereof, and
wherein administration of the first and second anti-cancer agents provides a synergistic effect compared to administration of either anti-cancer agent alone.
2. The method according to claim 1 , wherein the subject is a mammal.
3. The method according to claim 2 , wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.
4. The method according to claim 2 , wherein the mammal is a human.
5. The method according to claim 1 , wherein the subject with cancer has a somatic RAS or BRAF mutation.
6. The method according to claim 1 , wherein the cancer is selected from the group consisting of a cancer of the large intestine, breast cancer, pancreatic cancer, skin cancer, endometrial cancer, neuroblastoma, leukemia, lymphoma, liver cancer, lung cancer, testicular cancer, and thyroid cancer.
7. The method according to claim 1 , wherein the cancer is melanoma.
8. The method according to claim 1 further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of an antibody or fragment thereof, a cytotoxic agent, a drug, a toxin, a radionuclide, an immunomodulator, a photoactive therapeutic agent, a radiosensitizing agent, a hormone, an anti-angiogenesis agent, and combinations thereof.
9. The method according to claim 8 , wherein the additional therapeutic agent is an inhibitor of the PI3K/Akt pathway.
10. The method according to claim 9 , wherein the inhibitor of the PI3K/Akt pathway is selected from the group consisting of A-674563 (CAS #552325-73-2), AGL 2263, AMG-319, AS-041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), AS-604850 (5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione), AS-605240 (5-quinoxilin-6-methylene-1,3-thiazolidine-2,4-dione), AT7867 (CAS #857531-00-1), benzimidazole series, BML-257 (CAS #32387-96-5), CAL-120, CAL-129, CAL-130, CAL-253, CAL-263, CAS #612847-09-3, CAS #681281-88-9, CAS #75747-14-7, CAS #925681-41-0, CAS #98510-80-6, CCT128930 (CAS #885499-61-6), CH5132799 (CAS #1007207-67-1), CHR-4432, FPA 124 (CAS #902779-59-3), GS-1101 (CAL-101), GSK 690693 (CAS #937174-76-0), H-89 (CAS #127243-85-0), Honokiol, IC87114, IPI-145, KAR-4139, KAR-4141, KIN-1, KT 5720 (CAS #108068-98-0), Miltefosine, MK-2206 dihydrochloride (CAS #1032350-13-2), ML-9 (CAS #105637-50-1), Naltrindole Hydrochloride, OXY-111A, perifosine, PHT-427 (CAS #1191951-57-1), pictilisib, PIK-90 (CAS #677338-12-4), SC-103980, SF-1126, SH-5, SH-6, Tetrahydro Curcumin, TG100-115, Triciribine, X-339, XL-499, pharmaceutically acceptable salts thereof, and combinations thereof.
11. A method of treating or ameliorating the effects of a cancer in a subject in need thereof comprising administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is trametinib or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer,
wherein administration of the first and second anti-cancer agents provides a synergistic effect compared to administration of either anti-cancer agent alone.
12. The method according to claim 11 , wherein the subject is a mammal.
13. The method according to claim 12 , wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.
14. The method according to claim 12 , wherein the mammal is a human.
15. The method according to claim 11 , wherein the BVD-523 or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or diluent.
16. The method according to claim 11 , wherein the trametinib or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or diluent.
17. The method according to claim 11 , wherein the subject with cancer has a somatic RAS mutation or BRAF mutation.
18. The method according to claim 11 , wherein the cancer is selected from the group consisting of a cancer of the large intestine, breast cancer, pancreatic cancer, skin cancer, endometrial cancer, neuroblastoma, leukemia, lymphoma, liver cancer, lung cancer, testicular cancer, and thyroid cancer.
19. The method according to claim 11 , wherein the cancer is melanoma.
20. The method according to claim 11 further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of an antibody or fragment thereof, a cytotoxic agent, a drug, a toxin, a radionuclide, an immunomodulator, a photoactive therapeutic agent, a radiosensitizing agent, a hormone, an anti-angiogenesis agent, and combinations thereof.
21. The method according to claim 20 , wherein the additional therapeutic agent is an inhibitor of the PI3K/Akt pathway.
22. The method according to claim 21 , wherein the inhibitor of the PI3K/Akt pathway is selected from the group consisting of A-674563 (CAS #552325-73-2), AGL 2263, AMG-319, AS-041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), AS-604850 (5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione), AS-605240 (5-quinoxilin-6-methylene-1,3-thiazolidine-2,4-dione), AT7867 (CAS #857531-00-1), benzimidazole series, BML-257 (CAS #32387-96-5), CAL-120, CAL-129, CAL-130, CAL-253, CAL-263, CAS #612847-09-3, CAS #681281-88-9, CAS #75747-14-7, CAS #925681-41-0, CAS #98510-80-6, CCT128930 (CAS #885499-61-6), CH5132799 (CAS #1007207-67-1), CHR-4432, FPA 124 (CAS #902779-59-3), GS-1101 (CAL-101), GSK 690693 (CAS #937174-76-0), H-89 (CAS #127243-85-0), Honokiol, IC87114, IPI-145, KAR-4139, KAR-4141, KIN-1, KT 5720 (CAS #108068-98-0), Miltefosine, MK-2206 dihydrochloride (CAS #1032350-13-2), ML-9 (CAS #105637-50-1), Naltrindole Hydrochloride, OXY-111A, perifosine, PHT-427 (CAS #1191951-57-1), pictilisib, PIK-90 (CAS #677338-12-4), SC-103980, SF-1126, SH-5, SH-6, Tetrahydro Curcumin, TG100-115, Triciribine, X-339, XL-499, pharmaceutically acceptable salts thereof, and combinations thereof.
23. A method of effecting cancer cell death comprising contacting the cancer cell with an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 2 MEK inhibitor or a pharmaceutically acceptable salt thereof,
wherein the type 2 MEK inhibitor is selected from the group consisting of GDC-0623, MEK162, trametinib, pharmaceutically acceptable salts thereof, and combinations thereof, and
wherein administration of the first and second anti-cancer agents provides a synergistic effect compared to administration of either anti-cancer agent alone.
24. The method according to claim 23 , wherein the subject is a mammal.
25. The method according to claim 24 , wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.
26. The method according to claim 24 , wherein the mammal is a human.
27. The method according to claim 23 , wherein the type 2 MEK inhibitor is trametinib or a pharmaceutically acceptable salt thereof.
28. The method according to claim 23 , wherein the subject with cancer has a somatic RAS mutation or BRAF mutation.
29. The method according to claim 23 , wherein the cancer is selected from the group consisting of a cancer of the large intestine, breast cancer, pancreatic cancer, skin cancer, endometrial cancer, neuroblastoma, leukemia, lymphoma, liver cancer, lung cancer, testicular cancer, and thyroid cancer.
30. The method according to claim 23 , wherein the cancer is melanoma.
31. The method according to claim 23 further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of an antibody or fragment thereof, a cytotoxic agent, a drug, a toxin, a radionuclide, an immunomodulator, a photoactive therapeutic agent, a radiosensitizing agent, a hormone, an anti-angiogenesis agent, and combinations thereof.
32. The method according to claim 31 , wherein the additional therapeutic agent is an inhibitor of the PI3K/Akt pathway.
33. The method according to claim 32 , wherein the inhibitor of the PI3K/Akt pathway is selected from the group consisting of A-674563 (CAS #552325-73-2), AGL 2263, AMG-319, AS-041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), AS-604850 (5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione), AS-605240 (5-quinoxilin-6-methylene-1,3-thiazolidine-2,4-dione), AT7867 (CAS #857531-00-1), benzimidazole series, BML-257 (CAS #32387-96-5), CAL-120, CAL-129, CAL-130, CAL-253, CAL-263, CAS #612847-09-3, CAS #681281-88-9, CAS #75747-14-7, CAS #925681-41-0, CAS #98510-80-6, CCT128930 (CAS #885499-61-6), CH5132799 (CAS #1007207-67-1), CHR-4432, FPA 124 (CAS #902779-59-3), GS-1101 (CAL-101), GSK 690693 (CAS #937174-76-0), H-89 (CAS #127243-85-0), Honokiol, IC87114, IPI-145, KAR-4139, KAR-4141, KIN-1, KT 5720 (CAS #108068-98-0), Miltefosine, MK-2206 dihydrochloride (CAS #1032350-13-2), ML-9 (CAS #105637-50-1), Naltrindole Hydrochloride, OXY-111A, perifosine, PHT-427 (CAS #1191951-57-1), pictilisib, PIK-90 (CAS #677338-12-4), SC-103980, SF-1126, SH-5, SH-6, Tetrahydro Curcumin, TG100-115, Triciribine, X-339, XL-499, pharmaceutically acceptable salts thereof, and combinations thereof.